Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Cidara Therapeutics, Inc. - SIC # 2830 -
Ticker
Exchange
SIC #
Website
Latest Ticker
CDTX
Nasdaq
2830
www.cidara.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Cidara Therapeutics, Inc.
Cidara Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference
- Jan 30th, 2025 9:05 pm
Here’s Why Cidara Therapeutics, Inc. (CDTX) Is Skyrocketing
- Jan 13th, 2025 8:37 pm
Cidara achieves full enrolment in influenza prevention trial
- Dec 5th, 2024 4:07 pm
Cidara Therapeutics Completes Enrollment of Phase 2b NAVIGATE Trial Evaluating CD388 for Prevention of Seasonal Influenza
- Dec 4th, 2024 1:00 pm
Cidara Therapeutics (CDTX) Just Flashed Golden Cross Signal: Do You Buy?
- Dec 3rd, 2024 2:55 pm
Cidara Therapeutics Announces $105 Million Private Placement
- Nov 21st, 2024 1:30 pm
Cidara Therapeutics to Participate in Evercore 7th Annual HealthCONx Conference
- Nov 19th, 2024 1:00 pm
Cidara Therapeutics: Q3 Earnings Snapshot
- Nov 7th, 2024 10:09 pm
Cidara Therapeutics to Participate in Two Upcoming November Investor Conferences
- Oct 31st, 2024 12:00 pm
Cidara Therapeutics Announces Two Presentations on Drug-Fc Conjugate, CD388, at IDWeek 2024
- Oct 16th, 2024 12:00 pm
Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
- Oct 4th, 2024 8:30 pm
Cidara Therapeutics Announces Two Presentations on Innovative Drug-Fc Conjugate, CD388, at the 2024 OPTIONS XII for the Control of Influenza Conference
- Sep 25th, 2024 12:00 pm
Cidara Therapeutics Announces First Subjects Dosed in Phase 2b NAVIGATE Trial Evaluating CD388 for the Prevention of Seasonal Influenza
- Sep 23rd, 2024 12:00 pm
Cidara Therapeutics Strengthens its Scientific Advisory Board with Infectious Disease Experts
- Sep 19th, 2024 12:00 pm
Cidara axes 30% of staff to focus on flu prevention drug
- Sep 13th, 2024 2:13 pm
Cidara buys back rights to flu therapy from J&J for $85m
- Sep 13th, 2024 11:53 am
Cidara Therapeutics Restructures Workforce to Focus on Planned Clinical Development of CD388
- Sep 12th, 2024 8:05 pm
Cidara to Present at the H.C. Wainwright 26th Annual Global Investment Conference
- Sep 5th, 2024 12:00 pm
Cidara Therapeutics Announces Appointment of Jim Beitel as Chief Business Officer
- Aug 19th, 2024 9:12 pm
Cidara Therapeutics: Q2 Earnings Snapshot
- Aug 13th, 2024 9:25 pm
Scroll